| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [F-18]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET- patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET- patients (95% confidence interval [CI], 94%-99%) and 86% for PET- patients (95% CI, 78%-95%, P = .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET- patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact
- In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [F-18]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET- patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET- patients (95% confidence interval [CI], 94%-99%) and 86% for PET- patients (95% CI, 78%-95%, P = .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET- patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact (en)
- Autoři popisují negativní vliv pozitronového emisního tomografu na progresi raného relapsu pro pacienty s reziduálním onemocněním po první řadě chemoterapie u pokročilých stádií Hodgkinova lymfomu (cs)
|
| Title
| - Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
- Pozitronový emisní tomograf má negativní prediktivní hodnoty pro progresi raného relapsu pro pacienty s reziduálním onemocněním po první řadě chemoterapie u pokročilých stádií Hodgkinova lymfomu (cs)
- Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma (en)
|
| skos:prefLabel
| - Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
- Pozitronový emisní tomograf má negativní prediktivní hodnoty pro progresi raného relapsu pro pacienty s reziduálním onemocněním po první řadě chemoterapie u pokročilých stádií Hodgkinova lymfomu (cs)
- Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma (en)
|
| skos:notation
| - RIV/00216208:11120/08:00001283!RIV09-MZ0-11120___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/08:00001283
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - FDG-PET; free survival; early interim; therapy; regimen; radiotherapy; metaanalysis; standard; cycles; trials (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Marková, Jana
- Borchmann, P.
- Diehl, V.
- Eich, H. T.
- Engert, A.
- Fuchs, M.
- Dietlein, M.
- Kobe, C.
- Zijlstra, J. M.
- Franklin, J.
- Lorenz, R.
- Amthauer, H.
- Bares, R.
- Bockisch, A.
- Klutmann, S.
- Knapp, W. H.
- Lohri, A.
- Müller, R. P.
- Schicha, H.
- Schreckenberger, M.
- Weckesser, M.
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)